MADRID, Spain—Baxdrostat (AstraZeneca), an investigational aldosterone synthase inhibitor, provides substantial reductions in blood pressure when added to background therapy in patients with ...

Though other types of diet could be used to stave off diabetes, Salas-Salvadó said the Mediterranean diet—with a focus on ...

The drug reduced CV mortality but not HF hospitalizations, a disconnect that left some experts scratching their heads.

In the phase III trial, the monthly injectable lowered levels by nearly 60 percentage points vs placebo, but will it impact events?

The user-friendly approach helped diabetic patients get A1c levels under control and reduce the number of prescribed ...

Treatment with digitoxin cut the absolute risk of all-cause mortality and hospitalization for worsening HF by 4.6% compared with placebo over a median follow-up of 36 months (HR 0.82; 95% CI 0.69-0.98 ...

Whether it’s via an online program or simply a smartwatch, healthcare professionals stand to gain skills and insights.

It’s the first PCSK9 inhibitor to get the FDA’s approval for reducing MACE in patients without established cardiovascular ...

For the second time in 2 months, the agency has warned of a potential problem with the controllers, with one related death.

Patients with advanced heart failure, who are already followed closely, might be a good population to focus on, one expert says.

For patients with bicuspid aortic valve stenosis who undergo TAVI, rates of death or stroke are similar at 3 years, as well ...

Male and female patients had different outcomes, but before recommendations can be made, trials only in women are needed.